Checks the liver for fat and scarring in people with Cushing syndrome
Uses liver MRI to look for fatty liver in adults with Cushing syndrome.
Key facts
- Who runs it
- University Hospital, Angers
- Where
- Angers, Bordeaux, Brest, Grenoble, Lille, Nantes, and Vandœuvre-lès-Nancy, FranceSee the 7 sites
- Trial code
- Registry title
- NAC- NAFLD And Cushing
- Status
- Recruiting
- People taking part
- 100 people, planned
- Started
- 28 Sept 2023
- Expected to end
- 28 Sept 2029
- Type of study
- Interventional
- Treatments tested
- hepatic MRI
- Record updated
- 10 July 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with active Cushing's syndrome. It checks them for fatty liver and liver scarring using a liver MRI.
- Age
- Over 18 years
- Sex
- All sexes can join.
- Disease stage
- Active Cushing's syndrome
Main reasons for not taking part
- Other common causes of long-term liver disease (HBV, HCV, haemochromatosis, alcohol)
- Cannot have an MRI scan (contraindication to MRI)
The registry criteria, word for word
Show all 4 criteriaShow less
Who can take part
- Age > 18 years
- Active Cushing's syndrome
Who cannot take part
- Other common causes of chronic liver disease (HBV, HCV, haemochromatosis, alcohol)
- Contraindication to MRI
Where in France
- University Hospital AngersAngers, FranceContact: Claire BRIET, MDTaking people
- University Hospital BordeauxBordeaux, FranceContact: Amandine FERRIERE, PHDTaking people
- University Hospital BrestBrest, FranceContact: PHILIPPE TUILLIER, MDTaking people
- university Hospital GrenobleGrenoble, FranceContact: JUSTINE CRISTANTE, PHDTaking people
- University Hospital LilleLille, FranceContact: STEPHANIE ESPIARD, MDTaking people
- University Hospital NantesNantes, FranceContact: Sarra SMATI GRANGEON, PHDTaking people
- University Hospital, NancyVandœuvre-lès-Nancy, FranceContact: NICOLAS SCHEYER, PHDTaking people
About the trial
What the trial wants to find out
Cushing's Syndrome is a rare disease resulting from prolonged exposure to high levels of circulating cortisol. Clinical manifestations are variable but many patients present a metabolic syndrome (abdominal obesity, insulin resistance, dyslipidemia, hypertension). With regard to the liver, experimental data have shown that excess cortisol leads in an increase in lipogenesis and a reduction in the oxidation of fatty acids. This, in association with an accumulation of visceral adipose tissue and deregulation of adipokines, may contribute to the development of hepatic steatosis in animals. However, few data is available in humans with only one study of 50 patients with Cushing's syndrome estimating the prevalence of hepatic steatosis at 20%.
Read full original descriptionShow less
NAFLD (Non-Alcoholic Fatty Liver Disease), is defined as the presence of hepatic steatosis in the absence of secondary causes of intrahepatic fat accumulation. It is a heterogeneous disease ranging from simple liver steatosis, whose prognosis is generally considered to be benign, to inflammation (NASH, Non-Alcoholic Steato-Hepatitis) which may progress to fibrosis, cirrhosis and an increased risk of hepatocellular carcinoma. The prognosis for NAFLD is mainly related to the severity of hepatic fibrosis.
In Cushing's syndrome, normalization of cortisol production is the most effective strategy to improve co-morbidities associated with hypercortisolism. However, some of these complications, especially the metabolic co morbidities, could not be completely reversible and no data is available about resolution of hepatic steatosis.
The group in the trial
- open-label studyOther group
hepatic MRI, Fibroscan
Treatment: hepatic MRI
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Prévalence de la stéato-fibrose hépatique Dans le Syndrome de Cushing
- Plain-language title
- Checks the liver for fat and scarring in people with Cushing syndromeGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 10 July 2026